Vaxinano

Vaxinano is a clinical-stage biotech company specializing in the development of vaccines and therapies targeting zoonotic diseases, which are diseases that can be transmitted from animals to humans. The company operates in the biotech sector, focusing on creating solutions that cross the mucosal barrier to activate immune responses effectively. Vaxinano's business model revolves around its unique pipeline of vaccines and therapies, including the VXN TOXO vaccine against toxoplasmosis and the VXN LEISH immunotherapy against leishmaniasis. These products have demonstrated high immunogenicity, effectively preventing transmission and treating infections. The company collaborates with zoos worldwide through its WildVax Conservation Program, aiming to protect endangered and threatened species. Vaxinano generates revenue by partnering with these institutions and offering its vaccination programs. The company serves a diverse clientele, including zoos and wildlife conservation organizations, and operates in a global market with a mission to protect both animal and human health. Vaxinano's commitment to wildlife conservation is evident in its efforts to vaccinate over 600 primates in 24 zoos globally. The company's strategic focus on zoonosis and its dedication to preserving wildlife position it as a significant player in the biotech industry.

Keywords: zoonosis, vaccines, therapies, wildlife conservation, mucosal barrier, immunogenicity, toxoplasmosis, leishmaniasis, biotech, primates